1. Signaling Pathways
  2. Immunology/Inflammation
  3. NO Synthase
  4. iNOS Isoform

iNOS

iNOS, also known as NOS-2, is a 131 kDa mammalian protein composed of 1,153 amino acids, which are assembled into two major domains, a C-terminal reductase—containing a flavin mononucleotide (FMN) binding subdomain—and a N-terminal oxygenase.iNOS adopts a zinc-bridged, homodimeric quaternary structure that allows the enzyme to convert L-Arg to L-citrulline with the concomitant production of NO. This transformation is governed by an elaborate electron transport chain, involving the cofactors nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), heme, and (6R)-5,6,7,8-tetrahydrobiopterin (H4B), which are essential for this reaction. This process is mediated by CaM, which binds in a hinge region between the oxygenase and reductase domains.

iNOS Related Products (66):

Cat. No. Product Name Effect Purity
  • HY-P1956
    Human serum albumin
    Inhibitor 99.9%
    Human serum albumin (HSA) is the most abundant protein in plasma and is a major determinant of plasma oncotic pressure. Human serum albumin exhibits antioxidant, anticoagulant, anti-inflammatory, anti-platelet aggregation activities as well as colloid osmotic action. Human serum albumin can block the inhibitory effect of GML on human T cells, providing protective function for T cells. Human serum albumin is also associated with cardiovascular diseases and can partially prevent the LPS (HY-D1056) induced oxidative stress, as well as the upregulation of NF-κB, NF-κB, and peroxynitrite (ONOO) in the vascular wall, contributing to the reduction of blood pressure.
  • HY-18731
    1400W Dihydrochloride
    Inhibitor 99.94%
    1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18730). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a Kd value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation.
  • HY-N1445
    Isoquercitrin
    Inhibitor 99.87%
    Isoquercetin (Quercetin 3-glucoside) is a naturally occurring polyphenol that has antioxidant, anti-proliferative, and anti-inflammatory properties. Isoquercetin alleviates ethanol-induced hepatotoxicity, oxidative stress, and inflammatory responses via the Nrf2/ARE antioxidant signaling pathway. Isoquercetin regulates the expression of nitric oxide synthase 2 (NO2) via modulating the nuclear factor-κB (NF-κB) transcription regulation system. Isoquercetin has high bioavailability and low toxicity, is a promising candidate agent to prevent birth defects in diabetic pregnancies.
  • HY-18732A
    L-NMMA acetate
    Inhibitor 98.58%
    L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 µM, respectively.
  • HY-N2302
    Fucoxanthin
    Inhibitor 99.47%
    Fucoxanthin (all-trans-Fucoxanthin) is a marine carotenoid and shows anti-obesity, anti-diabetic, anti-oxidant, anti-inflammatory and anticancer activities.
  • HY-W022047
    nNOS-IN-1
    Inhibitor 99.37%
    nNOS-IN-1(Compound 14) is an inhibitor for nitric oxide synthases (NOS), that exhibits inhibitory activities against neuroal, inducible and endothelial NOS, with IC50s of 2.5, 5.7 and 13 μM, respectively.
  • HY-161513
    iNOS/COX-2-IN-1
    Inhibitor
    iNOS/COX-2-IN-1 (Compound 12e) is an inhibitor of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS). iNOS/COX-2-IN-1 inhibits the NF-κB and MAPKs signaling pathways and thus exerts anti-inflammatory effects.
  • HY-114798
    Rabelomycin
    Inhibitor
    Rabelomycin is antibiotic, which exhibits antimicrobial activity against gram positive bacteria. Rabelomycin exhibits inhibitory activity against inducible nitric oxide synthase (iNOS) with an IC50 of 63.9 μM.
  • HY-B2162
    Chondroitin sulfate
    98.60%
    Chondroitin sulfate, one of five classes of glycosaminoglycans, has been widely used in the treatment of osteoarthritis. Chondroitin sulfate reduces inflammation mediators and the apoptotic process and is able to reduce protein production of inflammatory cytokines, iNOS and MMPs.
  • HY-12116
    L-NIL
    Inhibitor 99.82%
    L-NIL is an inducible NO synthase inhibitor, with an IC50 of 3.3 μM for miNOS.
  • HY-N0904
    Ginsenoside C-K
    Inhibitor 99.92%
    Ginsenoside C-K, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects by reducing iNOS and COX-2. Ginsenoside C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively.
  • HY-N0635
    Prim-O-glucosylcimifugin
    Inhibitor 99.94%
    Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.
  • HY-N0006
    Demethoxycurcumin
    ≥99.0%
    Demethoxycurcumin is one of the main active ingredients of curcumin, which has anti-inflammatory, antioxidant, antibacterial, anti-cancer and neuroprotective effects. Demethoxycurcumin is orally active. Demethoxycurcumin can be used in inflammation, cancer and Alzheimer's disease research.
  • HY-100986
    L-NIO dihydrochloride
    Inhibitor
    L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats.
  • HY-12119A
    GW274150 phosphate
    Inhibitor 99.85%
    GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation.
  • HY-N1382
    Asperuloside
    Inhibitor 99.79%
    Asperuloside is an iridoid isolated from Hedyotis diffusa, with anti-inflammatory activity. Asperuloside inhibits inducible nitric oxide synthase (iNOS), suppresses NF-κB and MAPK signaling pathways.
  • HY-N0569
    Madecassic acid
    Inhibitor 99.23%
    Madecassic acid is isolated from Centella asiatica (Umbelliferae). Madecassic acid has anti-inflammatory properties caused by iNOS, COX-2, TNF-alpha, IL-1beta, and IL-6 inhibition via the downregulation of NF-κB activation in RAW 264.7 macrophage cells.
  • HY-13571A
    Beclometasone dipropionate
    Inhibitor 99.89%
    Beclometasone dipropionate, the proagent of Beclometasone, is an orally active and potent glucocorticoid recepter agonist. Beclometasone dipropionate acts via a glucocorticoid receptor and suppresses inflammation and hyperproliferation. Beclometasone dipropionate can be used for asthma .
  • HY-79457
    S-Methylisothiourea sulfate
    Inhibitor ≥98.0%
    S-Methylisothiourea sulfate is a potent, selective and competitive inhibitor of inducible nitric oxide synthase (iNOS). S-Methylisothiourea sulfate exerts beneficial effects in rodent models of septic shock.
  • HY-N6966
    Ethyl Caffeate
    Inhibitor 98.89%
    Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa. Ethyl caffeate suppresses NF-κB activation and its downstream inflammatory mediators, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2) in vitro or in mouse skin.